Juan Andres - 16 Jul 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
16 Jul 2021
Net transactions value
-$5,404,350
Form type
4
Filing time
20 Jul 2021, 16:15:51 UTC
Previous filing
16 Jul 2021
Next filing
23 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 16 Jul 2021 Direct F1
transaction MRNA Common Stock Sale $1,382,550 -5,000 -100% $276.51 0 16 Jul 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 19 Jul 2021 Direct F1
transaction MRNA Common Stock Options Exercise $122,100 +10,000 +200% $12.21* 15,000 19 Jul 2021 Direct F1
transaction MRNA Common Stock Sale $4,266,000 -15,000 -100% $284.40 0 19 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.1% $0.000000 439,822 16 Jul 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.1% $0.000000 434,822 19 Jul 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10,000 -2.3% $0.000000 424,822 19 Jul 2021 Common Stock 10,000 $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer